Advances in targeted therapeutic agents

Abstract A103: Preliminary results of a phase 1 study of FP-1039 (FGFR1:Fc), a novel antagonist of multiple fibroblast growth factor (FGF) ligands, in patients with advanced malignancies

(2012) A. Tolcher et al.   MOLECULAR CANCER THERAPEUTICS

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

(2010) B. Lowenberg et al.   BLOOD

Recombinant, ETA′-based CD64 immunotoxins: improved efficacy by increased valency, both in vitro and in vivo in a chronic cutaneous inflammation model in human CD64 transgenic mice

(2010) T. Ribbert et al.   BRITISH JOURNAL OF DERMATOLOGY

A Human Recombinant Autoantibody-Based Immunotoxin Specific for the Fetal Acetylcholine Receptor Inhibits Rhabdomyosarcoma Growth In Vitro and in a Murine Transplantation Model

(2010) S. Gattenlöhner et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

(2010) Frederick J Raal et al.   LANCET

ALK1-Fc Inhibits Multiple Mediators of Angiogenesis and Suppresses Tumor Growth

(2010) D. Mitchell et al.   MOLECULAR CANCER THERAPEUTICS

A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus

(2010) J. DeVincenzo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tumor Delivery and In Vivo Processing of Disulfide-Linked and Thioether-Linked Antibody−Maytansinoid Conjugates

(2009) Hans K. Erickson et al.   BIOCONJUGATE CHEMISTRY

Targeting tumor-associated macrophages in an experimental glioma model with a recombinant immunotoxin to folate receptor β

(2009) Taku Nagai et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors

(2009) W. P. Tew et al.   CLINICAL CANCER RESEARCH

Potent antibody drug conjugates for cancer therapy

(2009) Peter D Senter   CURRENT OPINION IN CHEMICAL BIOLOGY

Chemically modified cell-penetrating peptides for the delivery of nucleic acids

(2009) Maarja Mäe et al.   Expert Opinion on Drug Delivery

Venomics as a drug discovery platform

(2009) Pierre Escoubas et al.   Expert Review of Proteomics

A truncated soluble epidermal growth factor receptor-Fc fusion ligand trap displays anti-tumour activityin vivo

(2009) Timothy E. Adams et al.   GROWTH FACTORS

Annexin A2 Is a Molecular Target for TM601, a Peptide with Tumor-targeting and Anti-angiogenic Effects

(2009) Kamala Kesavan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Affitoxin—A Novel Recombinant, HER2-specific, Anticancer Agent for Targeted Therapy of HER2-positive Tumors

(2009) Rafal Zielinski et al.   JOURNAL OF IMMUNOTHERAPY

Engineering and Biological Characterization of VB6-845, an Anti-EpCAM Immunotoxin Containing a T-cell Epitope-depleted Variant of the Plant Toxin Bouganin

(2009) Jeannick Cizeau et al.   JOURNAL OF IMMUNOTHERAPY

Synthesis and Preliminary Biological Evaluation of High-Drug-Load Paclitaxel-Antibody Conjugates for Tumor-Targeted Chemotherapy

(2009) Sherly Quiles et al.   JOURNAL OF MEDICINAL CHEMISTRY

Phase I Clinical Study of Atacicept in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma

(2008) S. M. Ansell et al.   CLINICAL CANCER RESEARCH

Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer

(2008) Kim N Chi et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study of ACE-011 (ActRIIA-IgG1) in Postmenopausal Women*

(2008) Jon Ruckle et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

(2008) Jagath R Junutula et al.   NATURE BIOTECHNOLOGY

An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes

(2008) M. Onda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody

(2008) R. Bargou et al.   SCIENCE